Latest Conference Articles

March 20th 2022, 5:40pm

SGO Annual Meeting

Maintenance selinexor monotherapy was found to improve progression-free survival over placebo in patients with advanced or recurrent endometrial cancer.

March 20th 2022, 12:00pm

SGO Annual Meeting

The use of intraperitoneal carboplatin with paclitaxel improved progression-free survival, but not overall survival, vs intravenous chemotherapy in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

March 20th 2022, 12:00pm

SGO Annual Meeting

Mirvetuximab soravtansine was found to produce clinically meaningful antitumor activity with acceptable safety and tolerability in patients with platinum-resistant ovarian cancer and high folate receptor–alpha (FRα) expression.

March 19th 2022, 10:16pm

SGO Annual Meeting

The combination of nemvaleukin alpha and pembrolizumab led to encouraging clinical activity in patients with pretreated ovarian cancer who are resistant to platinum-based chemotherapy.

March 19th 2022, 6:46pm

SGO Annual Meeting

Atezolizumab given as an immune primer or concurrently with extended field chemoradiation demonstrated favorable progression-free survival and few dose-limiting toxicities, with evidence of T-cell clonal expansion in the tumors and peripheral blood of patients with locally advanced, node-positive cervical cancer.

March 19th 2022, 6:29pm

SGO Annual Meeting

Neoadjuvant niraparib induced strong results for patients with BRCA-mutant, homologous repair deficient–positive advanced resectable ovarian cancer.

March 19th 2022, 6:15pm

SGO Annual Meeting

Niraparib in combination with bevacizumab was efficacious following 1 line of platinum-based chemotherapy among patients with newly diagnosed advanced ovarian cancer, regardless of biomarker status.

March 19th 2022, 5:18pm

SGO Annual Meeting

Intravenous chemotherapy plus bevacizumab did not demonstrate differences in progression-free and overall survival compared with intraperitoneal chemotherapy plus bevacizumab in patients with advanced ovarian cancer with no macroscopic disease.

March 19th 2022, 5:15pm

SGO Annual Meeting

Single-agent olaparib generated similar overall survival compared with non-platinum chemotherapy in heavily pretreated patients with platinum-sensitive, relapsed ovarian cancer with BRCA mutations, according to the final analysis of the phase 3 SOLO3 trial.

March 19th 2022, 4:26pm

SGO Annual Meeting

Patient-reported outcome data support a favorable benefit/risk profile for the combination of pembrolizumab plus chemotherapy, with or without bevacizumab, in patients with persistent, recurrent, or metastatic cervical cancer.

March 18th 2022, 7:14pm

SGO Annual Meeting

The addition of ociperlimab to tislelizumab is under investigation in the phase 2 AdvanTIG-202 trial in patients with previously treated recurrent or metastatic cervical cancer.

March 18th 2022, 6:55pm

SGO Annual Meeting

Chinese investigators have launched CC-ANNIE, a phase 2 trial exploring anlotinib plus sintilimab for women with recurrent platinum-resistant ovarian clear cell carcinoma.

March 18th 2022, 5:38pm

SGO Annual Meeting

Patients with recurrent ovarian cancer who received PARP inhibitor maintenance treatment in the second-line setting experienced a longer time to next treatment and overall survival compared with those who were just under active surveillance.

March 16th 2022, 4:00pm

PER® New York GU

The applications for germline and somatic genetic testing in prostate cancer have skyrocketed, carving out an important role in screening, diagnosis, and treatment.

March 16th 2022, 2:00pm

PER® New York GU

Primo Nery Lara Jr, MD, provides an overview of the treatment landscape for patients with metastatic renal cell carcinoma.

March 16th 2022, 1:00pm

PER® New York GU

Immune checkpoint inhibitors represent only one area of effective therapy for patients with advanced prostate cancer, but they are not “be all, end all” of immunotherapy options.

March 15th 2022, 5:00pm

PER® New York GU

Overwhelming evidence has pointed to the use of androgen deprivation therapy in combination with 1 or 2 other agents as the standard of care for patients with metastatic castration-sensitive prostate cancer.

March 15th 2022, 1:00pm

Effective treatment paths leveraging neoadjuvant chemotherapy have been well-established for patients with muscle-invasive bladder cancer, with mounting retrospective and prospective data continuing to demonstrate overall survival benefit compared with adjuvant chemotherapy.

March 14th 2022, 2:13pm

PER® New York GU

Patients with metastatic urothelial carcinoma have multiple effective treatment options approved in both the first line and relapsed settings, with other promising agents and combinations currently in development.

March 5th 2022, 10:11pm

PER® Miami Breast Cancer Conference

Several factors aid treatment selection for patients with newly diagnosed metastatic triple-negative breast cancer, with upfront PD-L1 and BRCA testing being the most critical biomarkers to examine.